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Background: There is a socioeconomic gradient in the uptake of screening in the English NHS Bowel Cancer Screening
Programme (BCSP), potentially leading to inequalities in outcomes. We tested whether endorsement of bowel cancer screening
by an individual’s general practice (GP endorsement; GPE) reduced this gradient.
Methods: A cluster-randomised controlled trial. Over 20 days, individuals eligible for screening in England from 6480 participating
general practices were randomly allocated to receive a GP-endorsed or the standard invitation letter. The primary outcome was
the proportion of people adequately screened and its variation by quintile of Index of Multiple Deprivation.
Results: We enrolled 265 434 individuals. Uptake was 58.2% in the intervention arm and 57.5% in the control arm. After adjusting
for age, sex, hub and screening episode, GPE increased the overall odds of uptake (OR¼ 1.07, 95% CI 1.04–1.10), but did
not affect its socioeconomic gradient. We estimated that implementing GPE could result in up to 165 more people with high or
intermediate risk colorectal adenomas and 61 cancers detected, and a small one-off cost to modify the standard invitation
(d78 000).
Conclusions: Although GPE did not improve its socioeconomic gradient, it offers a low-cost approach to enhancing overall
screening uptake within the NHS BCSP.
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Colorectal cancer (CRC) is the fourth most common cause of
cancer death worldwide (Ferlay et al, 2013). In the UK it is the
third most common cancer and has the second highest mortality
rate (CRUK, 2014). Biennial screening using the guaiac faecal
occult blood test (gFOBt) can reduce bowel cancer mortality by up
to 25% among people undertaking screening (Hewitson et al, 2008;
Scholefield et al, 2012). The National Health Service (NHS) Bowel
Cancer Screening Programme (BCSP) introduced biennial screen-
ing in England in 2006 and now offers it to all individuals aged
60–74 years.
Screening uptake in England is 56%, varying from 61% in the
least deprived to 35% in the most-deprived areas of the country
(von Wagner et al, 2011).
The BCSP is delivered by five regional hubs and currently
operates independently from general practices. General practi-
tioners (GPs) are notified about their patients’ screening results or
if their patients did not have screening, but there is no organised
GP involvement. However, data from the BCSP pilot (2000–2002)
indicated that lack of GP involvement could be a significant barrier
to uptake (Weller et al, 2009), confirming findings from previous
studies that endorsement of the programme by a GP practice, or a
named GP, may circumvent lack of recognition of the BCSP and
enhance screening uptake (Cole et al, 2002; Zajac et al, 2010;
Hewitson et al, 2011). No evidence exists on whether GPE can
influence the differential uptake in CRC screening between
socioeconomic groups. Although the inclusion of the GP’s
signature on the screening invitation increases gFOBt uptake, this
is costly and time-consuming (Cole et al, 2002; Hewitson et al,
2011). Studies have also shown that naming the relevant general
practice is almost as effective at increasing uptake as including the
GP’s signature (Hewitson et al, 2011).
We developed four interventions to increase uptake amongst
individuals with lower socioeconomic circumstances (SEC),
without compromising uptake in any socioeconomic group
(Wardle et al, 2015). This paper reports the findings of a cluster-
randomised controlled trial (RCT) of one of these interventions:
general practitioner (GP) GP practice endorsement (GPE) of the
BCSP’s screening invitation, which could potentially be a simple and
cheap intervention to embed in the routine BCSP invitation letter.
One of the other three interventions that were developed, an
enhanced reminder letter targeted at individuals who had not
responded to the initial screening invitation, was evaluated at the
same time as GPE using a pseudo-factorial design. Patients were only
eligible for inclusion in the enhanced reminder study if they did not
respond to the initial screening invitation, and those who were
eligible were randomly assigned to receive the enhanced reminder or
not. Hence the enhanced reminder study is unlikely to affect the
evaluation of GPE.
In summary, the aims of this study were to evaluate the impact
of GPE on the socioeconomic gradient in CRC screening uptake,
and its cost. We also evaluated the impact of GPE on CRC
screening uptake overall.
MATERIALS AND METHODS
Intervention. We convened 18 focus groups in London and
Yorkshire to explore reasons for non-uptake of bowel cancer
screening amongst 128 individuals, sampled to encompass socially
advantaged and disadvantaged groups (Palmer et al, 2014). They
reported that lack of GP involvement attenuated the perceived
relevance of the BCSP and that GP support for the BCSP carried
considerable power (‘If the letter had come from my GPyI would
have taken it more seriously.’ (FG18P6)) (Palmer et al, 2014).
We established a Primary Care Advisory Group to develop GPE
text that could be easily incorporated into the standard BCSP
invitation. The resulting GPE statement appeared as a banner across
the invitation letter, linking it to each individual’s registered practice,
i.e., ‘Your GP Practice [GP practice name] supports the Bowel
Cancer Screening Programme’ (Supplementary Appendix A).
We sought consent from all General Practices in England
(N¼ 8142) to add their practice name to the standard BCSP
invitation. Letters to practices emphasised that endorsing the BCSP
would involve little or no extra work for the practice and were sent on
BCSP Hub headed paper, signed by Hub Directors. We sent up to
three reminder letters to practices at approximately monthly intervals.
The final reminder included an additional message for practices in
deprived areas, stating we were ‘particularly keen to include practices
that look after patients from more deprived areas because those
people are less likely to take part in screening’. In total, 80% of
practices (N¼ 6480) granted permission to be part of the study.
Randomisation and masking. Randomisation was undertaken
through the Bowel Cancer Screening System (BCSS), which
identifies the population eligible for screening in each hub. The
BCSS was modified to enable selection of invitees belonging to
general practices, which had agreed to endorse the BCSP before
creation of each invitation letter. Individual randomisation was not
feasible for logistical reasons: invitation letters are produced in
batches so it was not possible to vary them by individual screening
invitee, but it was possible to vary them by day. Therefore, cluster
randomisation was used based on day of invitation, with
‘day-within-hub’ constituting the randomisation unit (hub-day).
Randomisation ran over 20 consecutive days in June 2013,
resulting in 10 clusters of invitees receiving an endorsed invitation
letter and 10 control clusters in each of the five hubs (100 clusters
in total). Two weeks before the start of each intervention,
a random number sequence was generated with a continuous
random number for each hub-day. Hub-days above the median
random number were allocated to intervention; hub-days below to
control. This enabled the BCSS to take account of the dates when
GPE invitations needed to be produced by any of the five hubs.
Hubs were not aware of the randomisation schedule and confirmed
whether the intervention was included on the standard BCSP
invitation letter every day, which the Trial Office checked against
the randomisation schedule. Although blinding of hubs was not
possible, there was no direct contact with participants. Participants
were unaware of the comparator unless a household member
received an invitation during the study period that contained
different information materials or if they had been invited on a
previous occasion and recalled the content of that invitation.
Inclusion/exclusion criteria. Individuals were eligible for inclusion
in the GPE trial if registered with practices that had previously
agreed to endorse the BCSP. If the practice consent was not obtained,
individuals from that practice were excluded from the trial.
Outcome measures and costs. Participants were considered to
have been adequately screened if they had returned a gFOBt kit
within 18 weeks of being sent an invitation, which led to a
definitive ‘normal’ (no further investigation required) or ‘abnor-
mal’ (requiring referral for further investigation, usually colono-
scopy) test result. The 18-week time limit coincided with the date
on which the BCSS closes a screening episode to a non-responder.
Socioeconomic status was measured using the English Index of
Multiple Deprivation (IMD) 2010 (Indices of deprivation 2010,
2011), which comprises 38 indicators, combined into seven
domains (Income, Employment, Health and Disability, Education
Skills and Training, Barriers to Housing and Other Services, Crime
and Living Environment). This provides an overall measure of
deprivation experienced by people living in a small area (Lower
layer Super Output Area, LSOA). Each LSOA covers B1500
individuals. Each individual’s postcode was linked to the relevant
LSOA. Age and sex were obtained from the BCSP database, which
also contained information on the type of screening episode:
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whether individuals were being invited for the first time (first-time
invitee), being sent a biennial invitation having previously not
responded (previous non-responder), or being sent a biennial
invitation having been screened before (previous responder).
We used the results to estimate the impact of GPE on the
detection of colorectal adenomas and cancer in the BCSP.
We calculated the costs of modifying the BCSP IT system to
incorporate the GPE as part of the standard invitation. This was
based on the actual cost charged to the study to modify the invitation
letter. We divided this figure by the number of participants in the
intervention arm of the trial to calculate the cost per participant. No
additional intervention costs were incurred.
Statistical considerations. The sample size was based on increas-
ing uptake by five percentage points in the lowest IMD quintile
(most deprived group) falling to one percentage point increase in
the highest quintile; giving an overall 5-4-3-2-1 percentage point
difference by quintile. This estimate was based on outcomes
considered feasible in research to increase screening uptake
(Halloran et al, 2010). Sample size was calculated for each hub
separately, assuming a similar proportional effect in each hub. For
90% power to detect a statistical significant change as described
above, the estimated numbers required per group (intervention
and control) overall were 13 500, 12 200, 11 700, 5400 and 4500,
assuming that all participants had the composition of Midlands
and North West, London, North East, Eastern and Southern Hubs,
respectively. We used the maximum of the calculated sample sizes
(Midlands and North West Hub). Three further adjustments
ensured high statistical power. First, on average each hub sends
B3000 letters per day. The number of invitations per day varies, so
we applied an inflation factor of 1.7 to account for this. Second, we
initially predicted that 30% of practices would agree to endorse the
BCSP so we increased our sample size by a factor of 100/30, which
meant running the trial for 15 days to reach our target sample size
of 76 500. Third, we actually conducted the trial for 20 days.
We ran several logistic regression models, based on participant
level data with a binary outcome variable indicating whether or not
the participant was adequately screened (1¼ yes, 0¼ no). We ran a
univariable model on all participants regressing the outcome
against treatment group (1¼GPE intervention, 0¼ control)
(model 1). Model (2) was a multivariable model on all participants,
adjusting for sex, age, hub and screening episode. Models 1 and 2
were then performed stratifying participants by IMD quintile.
Model 1 was also performed stratifying participants by sex, age,
hub and screening episode, including an interaction term between
treatment group and IMD score (as a continuous variable). We
investigated whether GPE changed the socioeconomic gradient in
uptake (both univariable and multivariable models) by testing for
significant differences in the odds ratios (OR) for the treatment
group variable in each IMD quintile using Wald tests. Conservative
variance estimation was used to allow for correlation of individuals
within randomisation clusters but not between clusters, and we
used the Huber–White information sandwich method for variance
estimation (Huber, 1967; White, 1980).
We calculated average marginal effects and used these to predict
the impact of GPE on the detection of colorectal adenomas and
cancer in the BCSP.
Analyses were performed on an intention-to-treat basis using SAS
v9.3 (SAS Institute Inc., 2011) and Stata v12.1 (StataCorp, 2011).
Study approvals. Individual consent was not required because the
intervention took place as part of usual communication from the
BCSP. The activities of BCSP are covered by National Information
Governance Board approval with regard to the handling of patient-
identifiable data (Ref: PIAG 1–08(a)/2003). Ethical approval was
obtained from the UK National Research Ethics Service, London-
Harrow Ethics Committee, Reference number 12/LO/1396. This
study is registered at the ISRCTN (registration number: 74121020).
Role of the funding source. This is a summary of independent
research funded by the National Institute for Health Research
(NIHR)’s Programme Grants for Applied Research Programme (RP-
PG-0609–10106). The views expressed are those of the authors and not
necessarily those of the NHS, the NIHR or the Department of Health.
RESULTS
The trial included 265 434 individuals from 98 instead of 100
planned clusters (a protocol violation occurred in two clusters,
whereby incorrect randomisation was applied twice). Baseline
characteristics were well balanced between the two trial groups and
representative of the BCSP population (Table 1) (Logan et al,
2012). Bowel cancer screening uptake was 58.2 and 57.5% in the
GPE intervention and control groups, respectively (Table 2).
This increase of 0.7 percentage points (7 per 1000 screened
individuals) was statistically significant (Po0.001).
As expected, the absolute proportion of individuals participating
in screening decreased with increasing deprivation level: 65.2% of
individuals (average across both groups) in IMD quintile 1 (least
deprived) participated in screening, compared with 43.3% in IMD
quintile 5 (most deprived). Uptake was 0.8 percentage points lower
in the intervention group in the least deprived quintile and 1.4
percentage points higher in the most deprived quintile (Table 2).
Before adjustment, the GPE intervention had a non-significant
effect on the odds of screening uptake among all participants
(OR 1.03, 95% confidence interval (CI) 0.95–1.11, P¼ 0.49;
Table 3). Stratification by sub-group suggested there were
differences in the odds of screening uptake by screening history:
a 9% increase in the odds of uptake among first-time invitees
Table 1. Baseline sample characteristics
Standard BCSP
invitationþGPE
Standard BCSP
invitation
N¼131423 N¼134011
Median (range) Median (range)
Age (years)a 65 (59–74) 65 (59–74)
IMD deprivation score 14.7 (0.5–87.8) 14.6 (0.5–87.8)
% (n) % (n)
Sex
Female 51.0 (66 986) 51.2 (68 591)
Male 49.0 (64 437) 48.8 (65 420)
IMD quintileb
1 (Least deprived) 23.1 (30 350) 23.3 (31 381)
2 23.6 (30 952) 23.4 (31 340)
3 21.3 (27 950) 21.0 (28 181)
4 17.1 (22 450) 17.2 (23 007)
5 (Most deprived) 14.6 (19 174) 14.6 (19 540)
Missing 547 562
Hub
BCS01 27.4 (35 993) 25.8 (34 598)
BCS02 24.2 (31 760) 30.3 (40 550)
BCS03 9.0 (11 818) 9.9 (13 255)
BCS04 16.2 (21 272) 16.0 (21 439)
BCS05 23.3 (30 580) 18.0 (24 169)
Screening episode
Incident 52.3 (68 695) 52.3 (70 134)
Prevalent first time
invitees
17.0 (22 287) 17.6 (23 582)
Prevalent previous
non-responders
30.8 (40 441) 30.1 (40 295)
Abbreviations: BCSP¼Bowel Cancer Screening Programme; GPE¼GP endorsement;
IMD¼ Index of Multiple Deprivation.
aSome subjects were invited just before their 60th birthday.
bQuintile based on national distributions using pre-defined national cut-offs.
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(OR: 1.09; P¼ 0.02) and a 6% increase in the odds of uptake
among previous non-responders (OR: 1.06; P¼ 0.055); and in the
odds of uptake amongst previous responders (OR: 1.06; P¼ 0.045)
(Table 4). When the data were stratified by deprivation level, the
ORs in each IMD quintile were not significantly different from one
another (unadjusted ORs: 0.97, 1.02, 1.06, 1.06, 1.06 for the least to
most deprived IMD quintiles, respectively; P¼ 0.27; Table 3).
Interactions between treatment group and IMD score were
non-significant for all participants combined (P¼ 0.11), and were
largely non-significant in every sub-group (Table 4).
After adjusting for age, sex, hub and screening episode, the odds
of screening uptake were significantly higher in the intervention
arm (adjusted OR¼ 1.07, 95% CI 1.04–1.10, Po0.0001; Table 3),
i.e., a 7% increase in the odds of screening. A similar increase was
seen within each IMD quintile. However, the adjusted ORs in each
IMD quintile were not significantly different from one another
(P¼ 0.49); although the GPE intervention significantly increased
the overall screening uptake, it did not significantly affect the
socioeconomic gradient in screening uptake.
A 7% increase in the odds of screening (all participants) in the
multivariable model, was associated with predictive margins
(adjusted average probabilities of uptake) of 0.584 (95% CI
0.581–0.586) in the intervention group and 0.574 (95% CI
0.571–0.577) in the control group. This translates into a 1.7%
relative increase in the probability of screening among all
participants (0.584/0.574) and a one percentage point absolute
increase (0.584–0.574; the average marginal effect). Although this
appears to be a relatively small effect, in absolute terms the impact
would be large if it was rolled out nationally given the population
size. In the 2013/14 fiscal year, the number invited for screening in
the BCSP in England was 3 976 616 (BCSSN, 2015). An average
marginal effect of one percentage point (0.010) suggests that if GPE
were implemented nationally, then 39 766 extra people each year
would be screened. In 2013/14, the positivity rate among the
screened population was 1.84% (BCSSN, 2015). Evidence suggests
that 83% of people with a positive test result attend a specialist
screening practitioner clinic and undergo further investigation
(Logan et al, 2012), and among those who go on to have further
investigations, 10.1% will have a colorectal cancer, and 27.2% will
have colorectal adenomatous polyps classed as medium or high risk
requiring further investigation (Logan et al, 2012). Hence, if GPE
Table 2. Proportion of people who were adequately screened
by age, sex, IMD quintile, hub and screening episode
Standard BCSP
invitationþGPE
Standard BCSP
invitation
% (n) % (n)
All participants 58.2 (76 520) 57.5 (77 122)
Age (years)
60–64 55.9 (33 331) 54.8 (33 480)
65–69 61.0 (27 382) 60.5 (27 466)
70þ 58.7 (15 807) 58.8 (16 176)
Sex
Female 60.7 (40 707) 60.2 (41 290)
Male 55.5 (35 813) 54.8 (35 832)
IMD quintile
1 (Least deprived) 65.2 (19 792) 66.0 (20 716)
2 63.1 (19 530) 62.6 (19 604)
3 59.3 (16 571) 58.0 (16 336)
4 53.0 (11 902) 51.5 (11 839)
5 (Most deprived) 44.0 (8433) 42.6 (8324)
Hub
BCS01 55.2 (19 869) 55.4 (19 150)
BCS02 62.7 (19 915) 60.3 (24 437)
BCS03 49.5 (5850) 48.2 (6385)
BCS04 59.8 (12 710) 58.9 (12 631)
BCS05 59.4 (18 176) 60.1 (14 519)
Screening episode
Incident 86.4 (59 380) 85.7 (60 119)
Prevalent first time
invitees
51.4 (11 465) 49.4 (11 646)
Prevalent previous
non-responders
14.0 (5675) 13.3 (5357)
Abbreviations: BCSP¼Bowel Cancer Screening Programme; GPE¼GP endorsement;
IMD¼ Index of Multiple Deprivation. A total of 1109 (547 Standard BCSP invitationþGPE
and 562 Standard BCSP invitation) individuals had missing socioeconomic circumstances,
595 of these were adequately screened (292 Standard BCSP invitationþGPE and 303
Standard BCSP invitation).
Table 3. Impact on uptake of GPEþ standard BCSP invitation
vs standard BCSP invitation alone: results for all participants
combined and sub-groups of participants stratified by IMD
quintile
Univariate Multivariatea
Odds ratio
(95% CI) P-value
Odds ratio
(95% CI) P-value
All participants 1.03 (0.95–1.11) 0.49 1.07 (1.04–1.10) o0.0001
Participants stratified by IMD quintile
1 (Least deprived) 0.97 (0.88–1.05) 0.43 1.04 (0.99–1.08) 0.08
2 1.02 (0.95–1.10) 0.54 1.06 (1.02–1.10) 0.004
3 1.06 (0.98–1.14) 0.16 1.08 (1.03–1.13) 0.001
4 1.06 (0.98–1.16) 0.15 1.09 (1.04–1.15) 0.001
5 (Most deprived) 1.06 (0.97–1.15) 0.19 1.07 (1.01–1.13) 0.02
Test for equal
ORs in each IMD
quintile (P-value)
0.27 0.49
Abbreviations: CI¼ confidence interval; IMD¼ Index of Multiple Deprivation.
aAdjusting for age, sex, hub and screening episode.
Table 4. Impact on uptake of GPEþ standard BCSP invitation
versus standard BCSP invitation alone: univariate results for
all participants combined and sub-groups of participants
stratified by age, sex, hub and screening episode, plus
including an interaction term between treatment group and
IMD score (included as a continuous variable)
Odds ratio
(95%CI) P-value
P-value for
significant
interaction
with
IMD score
All participants 1.03 (0.95–1.11) 0.49 0.11
Participants stratified by sub-group
Age (years)
60–64 1.05 (0.98–1.12) 0.2 0.06
65–69 1.02 (0.92–1.13) 0.66 0.55
70þ 0.99 (0.89–1.10) 0.9 0.32
Sex
Female 1.02 (0.94–1.12) 0.58 0.22
Male 1.03 (0.96–1.12) 0.4 0.13
Hub
BCS01 0.99 (0.90–1.10) 0.91 0.42
BCS02 1.11 (0.99–1.24) 0.07 0.01
BCS03 1.05 (0.88–1.26) 0.56 0.95
BCS04 1.04 (0.94–1.14) 0.47 0.31
BCS05 0.97 (0.84–1.13) 0.73 0.25
Screening episode
Incident 1.06 (1.00–1.13) 0.045 0.68
Prevalent first time invitees 1.09 (1.01–1.16) 0.02 0.44
Prevalent previous non-
responders
1.06 (1.00–1.13) 0.055 0.22
Abbreviations: CI¼ confidence interval; IMD¼ Index of Multiple Deprivation.
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were implemented nationally this could detect up to an additional
165 people (39 766 0.0184 0.83 0.272) with polyps classed as
high or intermediate risk, and 61 people (39 766 0.0184 0.83
 0.101) with a colorectal cancer each year.
GPE incurred a one-off cost to modify the standard invitation
within the BCSS of d78 000. This is only 59 pence per participant
in the intervention arm of the trial. This would not need to be
incurred again if GPE were implemented. No additional costs were
incurred per person invited to screening, hence the average
marginal cost per GPE screening invitation was zero.
DISCUSSION
The addition of a simple statement of GP endorsement to the
standard BCSP invitation letter increased the odds of participation
in the gFOBt screening programme by 7% with only a small up-
front cost. This translates into a 1.7% relative increase in the
probability of screening and a 1% point absolute increase, and
represents an almost cost-free approach to enhancing screening
uptake, with no effort required from primary care other than
agreement to have the practice name on the letters.
GPE did not have a significantly stronger effect in lower vs
higher socioeconomic groups. This is the first study highly
powered to examine effects on the socioeconomic gradient, and
the size of the trial indicates that even if the non-significant
differences are real, they are not substantial, at least for the format
of GPE used.
The increase in overall uptake was smaller than previous studies
(Camilloni et al, 2013), which may be because they used a more
intensive intervention, with letters directly from the GP or
featuring individual GPs’ signatures. However, in the BCSP all
invitation letters come from the hubs and keeping up to date with
the names of all GPs at every practice would be costly, time
consuming and subject to error, as shown previously (Hewitson
et al, 2011). The only practical option was to include a banner
noting the individual’s general practice supported the programme.
Although this approach may have diluted the impact, this should
be balanced against the wide coverage, impact on colorectal
adenoma and cancer detection, and negligible cost.
The strengths of our trial were its national coverage, the large
sample size yielding substantial statistical power to detect small
differences in uptake between sub-groups, and easy incorporation
of the intervention into the existing BCSP.
There were several limitations. First, it was not possible to use
individual randomisation for logistical reasons so a clustered
design was used, which could compromise statistical efficiency and
increase the required sample size (Campbell, 2014). This was
addressed in our sample size calculation, and our sample size
target was surpassed. Second, contamination between study
groups, such that individuals in the control group were exposed
to the GPE intervention, could have occurred, for example, in the
unlikely event that different household members were randomised
to different arms of the trial during the 4-week study period. Third,
our findings may have been influenced by other factors operating
within areas and affecting outcomes. For example, it is possible that
local initiatives affected uptake in specific regions. This is unlikely
to affect our findings because it is improbable that concurrent
interventions would occur on the same alternate days as each
intervention. Fourth, as part of the programme, we developed four
interventions and another trial evaluating a simple enhanced
reminder was conducted at the same time as this trial using a
pseudo-factorial design. The enhanced reminders targeted indivi-
duals who had not responded to the initial screening invitation;
individuals who had not responded to the invitation were
randomly assigned to receive an enhanced reminder reiterating
the screening message or the usual reminder letter. Some
participants in the GPE trial were eligible for inclusion in the
enhanced reminder trial, and those who were not eligible had all
responded to the first screening invitation. Those who were eligible
for inclusion in the enhanced reminder study were randomly
allocated to receive the enhanced reminder or not. Hence, this has
not been adjusted for in our statistical analysis, though there is a
chance of residual confounding.
GP endorsement increased overall screening uptake although it
did not significantly affect the socioeconomic gradient in bowel
cancer screening participation. This illustrates the challenge of
shifting the gradient in screening participation within the context
of a national screening programme.
Given the exceptionally high level of agreement by general
practices to endorse the BCSP, the small one-off cost to modify
the standard invitation letter, and the overall increase in uptake, we
suggest that the BCSP consider adding GPE to the screening
invitation letter.
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